BC Extra | Oct 24, 2019
Preclinical News

Oct. 24 Preclinical Quick Takes: anti-neuraminidase human antibodies for broad flu protection; plus Ionis-Baylor, Merck and more

Broad influenza protection by human antibodies against neuraminidase  A Science study from Scripps Research Institute, Icahn School of Medicine at Mount Sinai and Washington University in St. Louis identified three human antibodies that could serve...
BC Innovations | May 23, 2019
Tools & Techniques

As polygenic risk scores mature, opportunities emerge for disease interception

With comprehensive genetic risk profiling inching closer to clinical use, the biggest opportunity for drug developers could be the new territory it opens up in disease prevention and interception, particularly for common diseases. Much of...
BC Extra | Nov 8, 2018
Preclinical News

Machine learning tool predicts template-free CRISPR editing

CRISPR veteran David Liu of the Broad Institute of MIT and Harvard and colleagues have developed a machine learning algorithm that predicts the genotypic result of CRISPR-mediated DNA breaks, suggesting CRISPR-based editing could be achieved...
BC Innovations | Oct 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Basal cell carcinoma (BCC) Mouse studies suggest combining LGR5, LRP6 or PORCN inhibitors with Erivedge vismodegib could help treat BCC. In two mouse models of BCC, diphtheria toxin-mediated depletion of LGR5 decreased tumor burden...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BC Innovations | Aug 30, 2018
Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
BC Week In Review | Aug 17, 2018
Financial News

RegenxBio raises $201.8M follow-on

RegenxBio Inc. (NASDAQ:RGNX) raised $201.8 million through the sale of 3.1 million shares at $65 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Raymond James. The number includes a 405,000 share...
BC Extra | Aug 13, 2018
Preclinical News

Polygenic scores increase disease risk prediction

Two studies in Nature Genetics suggest that aggregating SNPs, instead of assessing single SNPs, to generate risk scores from genome-wide association studies (GWAS) could improve predictions for disease risk. The use of individual gene variants...
BC Extra | Aug 10, 2018
Financial News

RegenxBio raises $175.5M follow-on

RegenxBio Inc. (NASDAQ:RGNX) raised $175.5 million through the sale of 2.7 million shares at $65 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Raymond James. On Wednesday, the company disclosed a...
BC Week In Review | Aug 10, 2018
Clinical News

RegenxBio discloses second serious AE for hypercholesterolemia gene therapy

RegenxBio Inc. (NASDAQ:RGNX) said RGX-501 led to a second treatment-related serious adverse event in a Phase I/II trial to treat homozygous familial hypercholesterolemia (HoFH). The open-label, international trial has enrolled six patients to receive a...
Items per page:
1 - 10 of 69